Literature DB >> 21415701

CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A.

Henry Y Dong1, Steven Wilkes, Haisu Yang.   

Abstract

Histology assessment of erythroid precursors in bone marrow biopsies can be challenging under pathologic conditions and often requires ancillary studies. CD71 (transferring receptor-1) is known to be expressed in the earliest erythroid precursors, and has been useful for flow cytometry. However, CD71 is also regarded as a proliferation marker, and its lineage specificity has not been systemically investigated by immunohistochemistry in detail. In this study, we found that CD71 was strongly expressed in all erythroid precursors in normal and dyspoietic marrows. Staining of CD71 effectively highlighted pronormoblasts in all 4 cases of parvovirus infection and erythroblasts in all 6 cases of acute erythroleukemia, for which staining of glycophorin A and hemoglobin A was either absent or unreliable. CD71 was absent in the background mature red blood cells in general, nonerythroid elements in the normal marrow, myeloid precursors in myeloproliferative disorders, and blasts in nearly all acute myeloid leukemia encompassing all common French-American-British subtypes. Benign lymphoid infiltrates and low-grade lymphomas involving the marrow also lacked detectable CD71. Although weak CD71 expression was found in acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and 1 of 2 cases of acute megakaryoblastic leukemia, it had little impact on interpretation due to a high signal-to-noise ratio of the staining intensities when compared with erythroid precursors in the same section. We conclude that CD71 is selectively expressed at high levels in erythroid precursors, including those at early maturation stages. It can be reliably used as an independent erythroid marker for immunohistochemical analysis of the marrow.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415701     DOI: 10.1097/PAS.0b013e31821247a8

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  28 in total

1.  Proteomic cornerstones of hematopoietic stem cell differentiation: distinct signatures of multipotent progenitors and myeloid committed cells.

Authors:  Daniel Klimmeck; Jenny Hansson; Simon Raffel; Sergey Y Vakhrushev; Andreas Trumpp; Jeroen Krijgsveld
Journal:  Mol Cell Proteomics       Date:  2012-03-27       Impact factor: 5.911

2.  Protein nanocages that penetrate airway mucus and tumor tissue.

Authors:  Xinglu Huang; Jane Chisholm; Jie Zhuang; Yanyu Xiao; Gregg Duncan; Xiaoyuan Chen; Jung Soo Suk; Justin Hanes
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

3.  Increased CD34+CD38 -CD123 + cells in myelodysplastic syndrome displaying malignant features similar to those in AML.

Authors:  Li Juan Li; Jing Lian Tao; Rong Fu; Hua Quan Wang; Hui Juan Jiang; Lan Zhu Yue; Wei Zhang; Hui Liu; Zong Hong Shao
Journal:  Int J Hematol       Date:  2014-05-21       Impact factor: 2.490

4.  Clonidine reduces norepinephrine and improves bone marrow function in a rodent model of lung contusion, hemorrhagic shock, and chronic stress.

Authors:  Ines G Alamo; Kolenkode B Kannan; Harry Ramos; Tyler J Loftus; Philip A Efron; Alicia M Mohr
Journal:  Surgery       Date:  2016-10-11       Impact factor: 3.982

5.  Triiodothyronine suppresses activin-induced differentiation of erythroleukemia K562 cells under hypoxic conditions.

Authors:  Yoritsuna Yamamoto; Mieno Shiraishi; Masanori Fujita; Itaru Kojima; Yuji Tanaka; Shoichi Tachibana
Journal:  Mol Cell Biochem       Date:  2014-03-07       Impact factor: 3.396

6.  Anti-CD71 antibody immunohistochemistry in the diagnosis of acute myeloid leukemia, subtype acute erythroid leukemia with erythroid dominance (AML M6-Er), in a retrovirus-negative cat.

Authors:  Satoshi Suzuki; Naotaka Ogino; Ikki Mitsui; Hiroyuki Ito; Takuro Kariya
Journal:  J Vet Diagn Invest       Date:  2020-11-22       Impact factor: 1.279

7.  De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity.

Authors:  Erica F Reinig; Patricia T Greipp; April Chiu; Matthew T Howard; Kaaren K Reichard
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

8.  The effects of selective beta-adrenergic blockade on bone marrow dysfunction following severe trauma and chronic stress.

Authors:  Elizabeth S Miller; Camille G Apple; Kolenkode B Kannan; Zackary M Funk; Philip A Efron; Alicia M Mohr
Journal:  Am J Surg       Date:  2020-07-25       Impact factor: 2.565

9.  α-Hemoglobin-stabilizing protein is a sensitive and specific marker of erythroid precursors.

Authors:  Philipp W Raess; Michelle E Paessler; Adam Bagg; Mitchell J Weiss; John Kim Choi
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

Review 10.  Erythroleukemia-historical perspectives and recent advances in diagnosis and management.

Authors:  Prajwal Boddu; Christopher B Benton; Wei Wang; Gautam Borthakur; Joseph D Khoury; Naveen Pemmaraju
Journal:  Blood Rev       Date:  2017-09-18       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.